Melanoma & Cutaneous Oncology Research Updates

In a Phase Ib trial of 12 patients with advanced melanoma or renal cell carcinoma, intramuscular personalized neoantigen synthetic long peptide vaccines with poly-ICLC were well tolerated (only grade 1–2 local pain or fever, no immune-mediated toxicities) and induced de novo CD8+ and CD4+ T‑cell responses detectable as early as one week. On average roughly half of vaccine peptides per patient were immunogenic, responses included IFN-γ–dominant CD8+ and TNF-α–dominant CD4+ phenotypes with increased effector memory differentiation, and tumor biopsies showed enhanced CD8+ infiltration with evidence of epitope spreading in some cases.

Among 465 patients with melanoma brain metastases treated with nivolumab plus ipilimumab, 392 discontinued treatment within 24 months and 73 continued beyond 24 months; patients who stopped after complete or partial response had overall survival and progression-free survival comparable to those who continued, with 4-year OS exceeding 83% after discontinuation for CR/PR or toxicity after CR. Multivariable analysis identified later-line therapy as associated with worse OS and presence of immune-related adverse events and stopping after CR/PR (or toxicity after CR) as associated with improved OS.

This review of melanoma surveillance notes that recurrence risk is highest within 2 years and that routine intensive imaging has not consistently improved survival while increasing costs and false positives. Emerging tools—circulating tumor DNA (ctDNA) and CD8-targeted PET—show promise for detecting molecular residual disease and visualizing T-cell dynamics respectively: persistent or new ctDNA after surgery is associated with worse recurrence-free survival but has variable sensitivity, and CD8 PET may predict immunotherapy response though it has timing, availability, cost, and functional-assessment limitations; prospective validation is required to define their clinical role.